Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 279 recruiting now early-phase tilt #6 of 28,963 conditions

Cancer: early-phase trial registry

279 of 621 indexed Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #6 of 28,963 conditions by registered trial count.

621 US clinical trials · 279 currently recruiting · #6 of 28,963 conditions by registered trial count

Cancer: 621 US clinical trials tracked, 279 recruiting.

Cancer is the subject of 621 registered US clinical trials on ClinicalTrials.gov, 279 of them currently open to new participants. 31 are in Phase 3-4 (later-stage) and 164 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 31 of these trials.

Open enrollment, early-phase tilt

Cancer has 621 registered US clinical trials, 279 of them open to new participants right now, about 45% of the total.

279
recruiting participants now
45%
of trials open to enrollment
31
in Phase 3-4 (later-stage)
31
top sponsor: M.D. Anderson Cancer Center

Corpus placement: #6 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.

Key findings

What ClinicalTrials.gov does not surface for Cancer on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.

  1. Cancer is recruiting above its size-band peers.

    279 of 621 indexed trials (44.9%) are open to enrollment, against a 37.2% average across 135 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Cancer trials is spread across many organizations.

    M.D. Anderson Cancer Center accounts for 31 of 621 trials (5%). 270 distinct sponsors appear on at least one study for this condition label.

  3. Typical Cancer enrolment sits around 108 participants.

    Median target enrolment is 108 among the 616 trials that report a genuine target (sentinel values excluded). 287 of those (46.6%) plan for fewer than 100 participants.

  4. Cancer research is mostly interventional.

    462 interventional and 159 observational studies make up this index (74.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 1116Phase 248Phase 327Phase 44

Open and recent trials

621 total, page 10 of 13

COMPLETED NA 130 participants

Financial Navigation Study Among Young Adult Blood Cancer Survivors

Tufts Medical Center

NCT05620979

COMPLETED NA 128 participants

Virtual Reality for Cancer Pain Management

Medstar Health Research Institute

NCT04572074

COMPLETED NA 126 participants

Implementing Personalized Exercise Prescriptions Through Mobile Health in the Elderly Cancer Survivors

University of Minnesota

NCT05069519

COMPLETED 120 participants

Fluorescence Bronchoscopy and Molecular Characterization of Abnormal Bronchial Lesions: Novel Approaches for Early Detection of Lung Cancer in High Risk Patients

National Institute of Environmental Health Sciences (NIEHS)

NCT00512642

COMPLETED Phase 1 114 participants

Study of Mogamulizumab + Nivolumab in Subjects w/Locally Advanced or Metastatic Solid Tumors

Kyowa Kirin

NCT02705105

COMPLETED Phase 2 114 participants

Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases

Stanford University

NCT00375830

COMPLETED 112 participants

Iron Overload in Patients Undergoing Donor Stem Cell Transplant

Masonic Cancer Center, University of Minnesota

NCT00888316

COMPLETED Phase 3 112 participants

Patient Controlled Methylphenidate for Cancer Related Fatigue: A Double Blind, Randomized, Placebo Controlled Trial

M.D. Anderson Cancer Center

NCT05041946

COMPLETED NA 110 participants

Pain Management in Cancer Patients Using a Mobile Application

Massachusetts General Hospital

NCT02069743

COMPLETED Phase 3 108 participants

PROStep: A Feasibility Trial Using PROs and Step Data to Monitor Patients With Lung and GI Cancers

Abramson Cancer Center at Penn Medicine

NCT04616768

COMPLETED Phase 2 105 participants

Study Comparing High-Dose Flu Vaccine to Standard Vaccine in Cancer Patients Less Than 65 Receiving Chemotherapy

Saad Jamshed MD

NCT01666782

COMPLETED Phase 1 103 participants

AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR

Amgen

NCT00770536

COMPLETED NA 102 participants

Pilot Study of a Decision Aid Intervention for Family-building After Cancer

Stanford University

NCT04059237

COMPLETED 102 participants

Investigation of Cisplatin-Related Kidney Toxicity

University of Chicago

NCT00984035

COMPLETED NA 100 participants

Psychological Intervention for Caregivers of Patients Undergoing Stem Cell Transplant

Massachusetts General Hospital

NCT03328663

COMPLETED NA 100 participants

A Study of Physical Activity in Cancer Survivors

Mayo Clinic

NCT05988892

COMPLETED 100 participants

Home Parenteral Nutrition in Cancer Patients

Southwestern Regional Medical Center

NCT01152879

COMPLETED NA 100 participants

Smartphone App for Cancer Medication Adherence

Columbia University

NCT05225090

COMPLETED 97 participants

A Complex Contraception Registry

University of California, San Diego

NCT02219269

COMPLETED Phase 1 94 participants

Study to Evaluate the Safety and Tolerability of IV Doses of BMS-906024 in Subjects With Advanced or Metastatic Solid Tumors

Bristol-Myers Squibb

NCT01292655

COMPLETED NA 92 participants

Pilot Optimization Trial of Decision Partnering Intervention for Advanced Cancer Family Caregivers

University of Alabama at Birmingham

NCT03947606

COMPLETED 88 participants

Parent Willingness to Participate in Tobacco Trials in the Pediatric Clinical Setting

St. Jude Children's Research Hospital

NCT01673243

COMPLETED Phase 4 88 participants

Study Using the MedPulser Electroporation System With Bleomycin to Treat Cutaneous and Subcutaneous Cancer

Inovio Pharmaceuticals

NCT00198276

COMPLETED NA 86 participants

Firefighter Soot, Sauna, and Sweat Excretion Pilot Study

HealthPartners Institute

NCT05256966

COMPLETED Phase 1 83 participants

Study of the Safety and Pharmacokinetics of XL765 (SAR245409) in Adults With Solid Tumors

Sanofi

NCT00485719

COMPLETED Phase 1 83 participants

AZD8330 First Time in Man in Patients With Advanced Malignancies

AstraZeneca

NCT00454090

COMPLETED Phase 2 80 participants

Radiation, Cetuximab and Pemetrexed With or Without Bevacizumab in Locally Advanced Head and Neck Cancer

University of Pittsburgh

NCT00703976

COMPLETED Phase 1 80 participants

ARQ 501 in Subjects With Cancer

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

NCT00075933

COMPLETED Phase 1 80 participants

Safety Study of XL765 (SAR245409) in Combination With Erlotinib in Adults With Solid Tumors

Sanofi

NCT00777699

COMPLETED NA 78 participants

Validation of Low Dose CT for Diagnosis of Lung Nodules

Children's Hospital Medical Center, Cincinnati

NCT03681873

COMPLETED Phase 1 77 participants

A Phase I, Open-Label, First-Time-In-Human Study of the Oral AKT Inhibitor GSK2141795

GlaxoSmithKline

NCT00920257

COMPLETED 77 participants

The Feasibility of Text Messaging to Assess Secondhand Smoke Exposure Among Youngsters With Cancer or Sickle Cell Disease

St. Jude Children's Research Hospital

NCT01591187

COMPLETED Phase 1 75 participants

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

National Institutes of Health Clinical Center (CC)

NCT00020579

COMPLETED NA 72 participants

Physical Activity and Healthy Eating Among Young Adult Cancer Survivors

UNC Lineberger Comprehensive Cancer Center

NCT05887401

COMPLETED 70 participants

C-Reactive Protein as a Predictor of Stem Cell Transplant Complications

Ann & Robert H Lurie Children's Hospital of Chicago

NCT00179868

COMPLETED Phase 1 70 participants

Study of Oral PQR309 in Patients With Advanced Solid Tumors

PIQUR Therapeutics

NCT02483858

COMPLETED NA 70 participants

A Pilot Feasibility Trial of a Tailored Intervention to Improve Adherence in Adolescents and Young Adults With Cancer

Children's Hospital Medical Center, Cincinnati

NCT05706610

COMPLETED Phase 1 68 participants

A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients

Arbutus Biopharma Corporation

NCT01262235

COMPLETED NA 68 participants

Stepped-Care Telehealth for Distress in Cancer Survivors

Wake Forest University Health Sciences

NCT03060096

COMPLETED NA 64 participants

Mind-body Resiliency Intervention for Fear of Cancer Recurrence

Massachusetts General Hospital

NCT04876599

COMPLETED NA 63 participants

Mobile Weight Loss Intervention for Adolescent and Young Adult Cancer Survivors

UNC Lineberger Comprehensive Cancer Center

NCT06171945

COMPLETED Phase 2 63 participants

Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC)

Amgen

NCT00413283

COMPLETED Phase 1 60 participants

A Study of the Alternative Administration of Ixabepilone and Vinflunine

Bristol-Myers Squibb

NCT00362830

COMPLETED Phase 3 60 participants

A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy

AbbVie

NCT03941964

COMPLETED NA 60 participants

Expressive Helping for Chinese-Speaking Cancer Patients and Survivors

New York University

NCT03945734

COMPLETED NA 60 participants

Cancer Care Coordination for Chemotherapy Patients

University of California, Davis

NCT02238951

COMPLETED NA 59 participants

Smoking Cessation Smartphone App for Cancer Patients (Quit2Heal Study)

Fred Hutchinson Cancer Center

NCT03600038

COMPLETED NA 57 participants

Promoting Quality of Life Among Young Adult Cancer Survivors

Emory University

NCT03446105

COMPLETED NA 56 participants

Sleep Treatment Education Program for Young Adult Cancer Survivors (STEP-YA)

Dana-Farber Cancer Institute

NCT05358951

COMPLETED Phase 1 56 participants

Study of REGN1400 Alone and in Combination With Erlotinib or Cetuximab in Patients With Certain Types of Cancer

Regeneron Pharmaceuticals

NCT01727869

← Previous Page 10 of 13 Next →

Phase Distribution

PhaseTrial count
Phase 1 116
Phase 2 48
Phase 3 27
Phase 4 4

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What is open for Cancer right now

279 recruiting of 621 indexed (45% open).

Phase mix: 31 late (III/IV) vs 164 early (I/II) (early-phase heavy).

Top sponsor: M.D. Anderson Cancer Center (31 trials), 9 others listed. 50 shown below, recruiting first. #6 of 28,963 conditions by registered trial count.

How open-enrollment share is computed

Open share is recruiting_count divided by trial_count for this condition label in the public registry export. Status can change between pulls; treat the figure as a snapshot of research attention, not treatment availability.

Frequently Asked Questions

How many clinical trials are there for Cancer?

PlainTrial tracks 621 US clinical trials for Cancer, of which 279 are currently recruiting participants. Data sourced from ClinicalTrials.gov.

How do I find a recruiting trial for Cancer?

Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.

Is this data current?

Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.

Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.

Verify with NIH →

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.